- Home
- FEBO vs BIAF Comparison
FEBO vs BIAF Comparison
Compare FEBO & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FEBO
- BIAF
- Stock Information
- Founded
- FEBO 1993
- BIAF 2014
- Country
- FEBO Hong Kong
- BIAF United States
- Employees
- FEBO N/A
- BIAF N/A
- Industry
- FEBO
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- FEBO
- BIAF Health Care
- Exchange
- FEBO Nasdaq
- BIAF Nasdaq
- Market Cap
- FEBO 8.3M
- BIAF 7.6M
- IPO Year
- FEBO 2023
- BIAF 2022
- Fundamental
- Price
- FEBO $0.73
- BIAF $2.48
- Analyst Decision
- FEBO
- BIAF Hold
- Analyst Count
- FEBO 0
- BIAF 1
- Target Price
- FEBO N/A
- BIAF N/A
- AVG Volume (30 Days)
- FEBO 54.0K
- BIAF 5.8M
- Earning Date
- FEBO 10-24-2025
- BIAF 11-13-2025
- Dividend Yield
- FEBO N/A
- BIAF N/A
- EPS Growth
- FEBO N/A
- BIAF N/A
- EPS
- FEBO N/A
- BIAF N/A
- Revenue
- FEBO $17,110,653.00
- BIAF $7,681,059.00
- Revenue This Year
- FEBO N/A
- BIAF N/A
- Revenue Next Year
- FEBO N/A
- BIAF $20.04
- P/E Ratio
- FEBO N/A
- BIAF N/A
- Revenue Growth
- FEBO 11.58
- BIAF 4.99
- 52 Week Low
- FEBO $0.61
- BIAF $2.34
- 52 Week High
- FEBO $5.20
- BIAF $67.12
- Technical
- Relative Strength Index (RSI)
- FEBO 48.60
- BIAF 47.39
- Support Level
- FEBO $0.70
- BIAF $2.36
- Resistance Level
- FEBO $0.81
- BIAF $7.29
- Average True Range (ATR)
- FEBO 0.08
- BIAF 0.71
- MACD
- FEBO 0.00
- BIAF -0.38
- Stochastic Oscillator
- FEBO 56.90
- BIAF 1.62
About FEBO Fenbo Holdings Limited
Fenbo Holdings Ltd is a company engaged in producing premium personal care electric appliances, principally electrical hair styling products such as straighteners, curlers, trimmers, etc., and toy products to overseas markets. It manufactures and sells products such as Straightener, Mini Straightener, and Curling Iron.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.